僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Canakinumab （ACZ885） is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin